InsidersTradesSigma
Total declarations
Companies
▲ Purchases (4 ops.)
▼ Sales (0 ops.)
Discover the full record of transactions filed by RICHMAN ERIC I, Chairman & CEO. Director active across 2 companies, notably Gain Therapeutics, Inc.. Cumulatively, 6 reports have been published. Total volume traded: €51k. The latest transaction was filed on 25 May 2022 — Acquisition. Regulator: SEC (Form 4). The full history is accessible without signup.
Declarations6 total
€5,9922,482 shares@ €2.41420.0080% mcap5.2% of flow
Common stock
SEC:0001415889-22-005798:0·
Ideal exit: 19 Feb 2023 (T+270)
€10,2474,000 shares@ €2.56170.014% mcap8.9% of flow
Common stock
SEC:0001415889-22-005501:0·
Ideal exit: 13 Feb 2023 (T+270)
€32,8664,922 shares@ €6.67740.044% mcap28.6% of flow
Common Stock
SEC:0001209191-22-025180:0·
Ideal exit: 13 May 2022 (T+270)
€2,2261,580 shares@ €1.4087100.0% of flow
Common stock
SEC:0001104659-22-031172:0·
Ideal exit: 26 Nov 2022 (T+270)
€32,8664,922 shares@ €6.6774100.0% of flow
Common Stock
SEC:0001104659-21-107121·
€32,8664,922 shares@ €6.67740.044% mcap28.6% of flow
Common Stock
SEC:0001104659-21-107121:0·
6 of 6 declarations
About RICHMAN ERIC I
Eric I. Richman is a Director and Chief Executive Officer of Gain Therapeutics, Inc. and NeuBase Therapeutics, Inc. In these roles, he oversees the operations of the companies and is responsible for the overall strategy. Eric leverages his expertise to lead these companies towards growth and innovation initiatives.
